Frontiers in Cardiovascular Medicine

JANUARY 31, 2024

Background Pulmonary vein isolation with wide antral ablation leads to better clinical outcomes for the treatment of atrial fibrillation, but the isolation lesion is invisible in conventional cryoballoon ablation. The rate of 12-month freedom from clinical atrial arrhythmia recurrence was 85.1% min vs. 23.76 ± 8.36 min,

Atrial Fibrillation 64

Atrial Fibrillation Ablation Pulmonary Outcomes 64

HeartRhythm

JANUARY 27, 2025

The results of pulmonary vein isolation are limited by arrhythmia recurrence, which is most often due to a failure to effectuate a durable contiguous circumferential transmural lesion around the pulmonary vein (PV) ostia.

Pulmonary 40

Pulmonary Ablation Arrhythmia 40

DAIC

MARCH 28, 2024

a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTec h i , announced the submission of the VARIPULSE Platform for Premarket Approval Application (PMA) to the U.S. 1,ii For patients who had received ablation, median procedure and fluoroscopy times were 90.0 Food & Drug Administration ( FDA ).

Atrial Fibrillation 110

Atrial Fibrillation AFIB Ablation Pulmonary 110

Frontiers in Cardiovascular Medicine

JANUARY 15, 2024

Background Catheter ablation (CA) for symptomatic atrial fibrillation (AF) offers the best outcomes for patients. Despite the benefits of CA, a significant proportion of patients suffer a recurrence; hence, there is scope to potentially improve outcomes through technical innovations such as ablation index (AI) guidance during AF ablation.

Ablation 64

Ablation Atrial Fibrillation BMI Arrhythmia 64

DAIC

JULY 24, 2024

Volta Medical has announced it has entered into a Joint Development Agreement with GE Healthcare to enhance arrhythmia procedures with artificial intelligence (AI)-driven electrophysiology technologies. Our mission to combat complex heart rhythm diseases relies on optimizing interoperability. The company has obtained U.S.

Atrial Fibrillation 105

Atrial Fibrillation AFIB Ablation Technology 105

HeartRhythm

JANUARY 7, 2025

Patients with D-transposition of the great arteries (D-TGA) palliated with atrial switch often develop atrial arrhythmias (AA) requiring pulmonary venous atrium (PVA) access for ablation, which can be achieved via retrograde aortic approach (RAA) or trans-baffle access (TBA).13

Arrhythmia 45

Arrhythmia Aortic Ablation Pulmonary 45

Journal of Cardiovascular Electrophysiology

DECEMBER 10, 2024

Pulsed field ablation (PFA) may overcome the disadvantages of thermal energy and improve both ablation efficacy and safety. Objective We report the feasibility, safety, and clinical efficacy of focal monopolar PFA in patients with the origin of their atrial arrhythmia in the SVC.

Arrhythmia 40

Arrhythmia Ablation Pulmonary Tachycardia 40

European Journal of Heart Failure

FEBRUARY 25, 2025

Overview of the study population and effects observed after catheter ablation for atrial fibrillation. PVI, pulmonary vein isolation. Herein we describe the effects of catheter ablation on AF burden, arrhythmia recurrences, and ventricular function in end-stage HF. to 39.18.3% ( p <0.001) following ablation.

Atrial Fibrillation 40

Atrial Fibrillation Ablation Heart Failure Arrhythmia 40

Journal of Cardiovascular Electrophysiology

MARCH 27, 2025

ABSTRACT Background Ultra-low temperature cryoablation (ULTC) is a technique designed to rapidly cool cardiac tissue to extremely low temperatures, enabling the creation of ablation lesions for the treatment of atrial fibrillation (AF). Arrhythmia outcomes after repeat ablation were evaluated.

Atrial Fibrillation 40

Atrial Fibrillation Ablation Arrhythmia Bicuspid/Mitral 40

Open Heart

DECEMBER 18, 2024

Introduction Pulsed-field ablation (PFA) is a novel modality for pulmonary vein isolation in patients with atrial fibrillation (AF). first-time AF ablation. first-time AF ablation. In first-time ablation cases, acute isolation of all pulmonary veins was achieved in 99.5% The patients were 32.1% of patients.

Atrial Fibrillation 52

Atrial Fibrillation Ablation Pulmonary Arrhythmia 52

HeartRhythm

APRIL 30, 2024

Despite advances, catheter ablation success rates for persistent AF remain at 50-60%. The approach for recurrent persistent AF, beyond pulmonary vein isolation, remains contentious. Surgical maze procedures have demonstrated superior outcomes compared to catheter ablation.

Ablation 40

Ablation Arrhythmia Pulmonary Outcomes 40

Journal of Cardiovascular Electrophysiology

DECEMBER 7, 2023

Abstract Background The newly introduced nonthermal pulsed field ablation (PFA) is a promising technology to achieve fast pulmonary vein isolation (PVI) with high acute success rates and good safety features. Data comparing PFA to VHPSD-PVI is lacking. For PFA-PVI a pentaspline 20 electrode catheter was used.

Ablation 40

Ablation Pulmonary Arrhythmia Atrial Fibrillation 40

Journal of Cardiovascular Electrophysiology

OCTOBER 19, 2023

Abstract The QDOT MICRO™ Catheter is a novel open-irrigated contact force-sensing radiofrequency ablation catheter. It offers very high-power short-duration (vHPSD) ablation with 90 W for 4 s to improve safety and efficacy of catheter ablation procedures.

Arrhythmia 40

Arrhythmia Ablation Atrial Flutter Atrial Fibrillation 40

All About Cardiovascular System and Disorders

MAY 18, 2024

Pulsed Field Ablation is a relatively new modality for treatment of atrial fibrillation. In conventional ablation for atrial fibrillation, either heating of tissue is produced by radiofrequency application or freezing of tissues by cryoablation. Pulsed field ablation group had 305 patients while thermal ablation group had 302 patients.

Ablation 40

Ablation Atrial Fibrillation Pulmonary Arrhythmia 40

Circulation: Arrhythmia and Electrophysiology

JANUARY 29, 2024

Circulation: Arrhythmia and Electrophysiology, Ahead of Print. BACKGROUND:High-power short-duration ablation has shown impressive efficacy and safety for pulmonary vein isolation (PVI); however, initial efficacy results with very high power short-duration ablation were discouraging. No complications occurred.

Electrophysiology 76

Electrophysiology Atrial Fibrillation Pulmonary Ablation 76

Circulation: Arrhythmia and Electrophysiology

DECEMBER 19, 2024

Circulation: Arrhythmia and Electrophysiology, Ahead of Print. We investigate whether additional linear ablation from the superior vena cava to the right atrial septum and cavotricuspid isthmus ablation improves the rhythm outcome of patients with persistent AF undergoing cryoballoon PVI (Cryo-PVI).METHODS:In

Atrial Fibrillation 40

Atrial Fibrillation Ablation Arrhythmia Pulmonary 40

Frontiers in Cardiovascular Medicine

FEBRUARY 17, 2025

Backgroundwide antral pulmonary vein isolation (PVI) is effective for treating paroxysmal atrial fibrillation (PAF), although time-demanding. Procedural data and electrophysiology (EP) laboratory times were systematically collected and analyzed.

Atrial Fibrillation 52

Atrial Fibrillation Ablation Laboratory Electrophysiology 52

Open Heart

JANUARY 18, 2024

Introduction Three recent randomised controlled trials have demonstrated that pulmonary vein isolation as an initial rhythm control strategy with cryoablation reduces atrial arrhythmia recurrence in patients with symptomatic paroxysmal atrial fibrillation (PAF) compared with antiarrhythmic drug (AAD) therapy. ablations over a lifetime.

Atrial Fibrillation 69

Atrial Fibrillation Ablation Pulmonary Arrhythmia 69

Dr. S. Venkatesan MD

APRIL 28, 2024

Both atria develop from a combination of the primitive atrium, sinus venous, and pulmonary veins.It Spatial relationship of sites for atrial fibrillation drivers and atrial tachycardia in patients with both arrhythmias July 2017 International Journal of Cardiology 248(3) AF begets AF. Let us see few factors.

Atrial Fibrillation 75

Atrial Fibrillation Bicuspid/Mitral Pulmonary Ablation 75

HeartRhythm

APRIL 30, 2024

Animal studies suggest that catheter ablation-associated parasympathetic and sympathetic denervation could result in increased ventricular arrhythmias (VA). The impact of catheter ablation of atrial fibrillation on VA burden in humans has not been assessed.

Atrial Fibrillation 40

Atrial Fibrillation Arrhythmia Ablation Pulmonary 40

HeartRhythm

JULY 30, 2024

Extra-pulmonary vein (PV) triggers have been reported in up to 4.9-15% 15% of all atrial fibrillation (AF) patients who undergo catheter ablation and plays significant roles in arrhythmia recurrence.1,2 Extra-pulmonary vein (PV) triggers have been reported in up to 4.9-15%

Aneurysm 40

Aneurysm Ablation Atrial Fibrillation Pulmonary 40

HeartRhythm

NOVEMBER 27, 2023

Pulsed field ablation (PFA) is a nonthermal energy source for ablation of cardiac arrhythmias. This study investigated the prospective outcomes of a novel PFA generator in conjunction with a commercially available, contact force-sensing, focal ablation catheter.

Ablation 40

Ablation Pulmonary Arrhythmia Outcomes 40

HeartRhythm

JULY 14, 2024

Pulsed field ablation (PFA) has become increasingly important in the treatment of cardiac arrhythmias. In addition to single-shot devices mainly used for pulmonary vein isolation, focal PFA may provide a treatment option that increases the versatility of the technique.

Ablation 40

Ablation Tachycardia Pulmonary Arrhythmia 40

HeartRhythm

APRIL 30, 2024

Pulsed field ablation (PFA) is an emerging technology that applies high voltage electrical pulses to cardiac tissue selectively and induces cell death through predominately non-thermal irreversible electroporation.

Ablation 40

Ablation Arrhythmia Technology Pulmonary 40

Circulation: Arrhythmia and Electrophysiology

DECEMBER 16, 2024

Circulation: Arrhythmia and Electrophysiology, Ahead of Print. Patients were randomly assigned to either the PVI+SVC ablation group or the PVI-only group. CONCLUSIONS:The addition of SVC ablation to PVI did not enhance freedom from atrial tachyarrhythmia at 12 months, and it led to increased complications. versus 72%;P=0.41).

Ablation 40

Ablation Atrial Fibrillation Electrophysiology Pulmonary 40

Circulation: Arrhythmia and Electrophysiology

NOVEMBER 23, 2023

Circulation: Arrhythmia and Electrophysiology, Ahead of Print. Background:Pulsed field ablation (PFA) has emerged as an alternative to radiofrequency ablation. A contact force–sensing catheter was used to focally deliver PFA/radiofrequency at the pulmonary veins and other predefined sites in the atria.

Ablation 40

Ablation Pulmonary Atrial Fibrillation Electrophysiology 40

Journal of Cardiovascular Electrophysiology

NOVEMBER 21, 2023

In this large substudy of the AWARE Trial, a high-power short-duration (HPSD) radiofrequency ablation strategy was found to be similarly effective as a low-power long-duration strategy with no difference in time to first recurrence of any AF lasting ≥30 s. Methods Patients were grouped according to a HPSD (≥40 W) or LPLD (≤35 W) strategy.

Ablation 40

Ablation Pulmonary Atrial Fibrillation Arrhythmia 40

DAIC

DECEMBER 26, 2023

a company primarily focused on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, announced the completion of the first five procedures in its first-in-human feasibility study with its novel CellFX nsPFA cardiac catheter.

Ablation 59

Ablation Atrial Fibrillation Technology Cardiothoracic 59

Circulation: Arrhythmia and Electrophysiology

NOVEMBER 3, 2023

Circulation: Arrhythmia and Electrophysiology, Volume 16, Issue 11 , Page e012043, November 1, 2023. BACKGROUND:In patients with persistent atrial fibrillation (PersAF), catheter ablation aiming for pulmonary vein isolation (PVI) is associated with moderate clinical effectiveness.

Atrial Fibrillation 40

Atrial Fibrillation Pulmonary Quality of Life Ablation 40

Circulation: Arrhythmia and Electrophysiology

DECEMBER 19, 2024

Circulation: Arrhythmia and Electrophysiology, Ahead of Print. BACKGROUND:Pulsed field ablation (PFA) is a promising treatment for atrial fibrillation. One-year freedom from atrial arrhythmia was 80.2% (95% CI, 69.7%87.4%) One-year freedom from atrial arrhythmia was 80.2% (95% CI, 69.7%87.4%) paroxysmal, and 58.5%

Atrial Fibrillation 40

Atrial Fibrillation Ablation Arrhythmia Outcomes 40

Circulation: Arrhythmia and Electrophysiology

NOVEMBER 29, 2024

Circulation: Arrhythmia and Electrophysiology, Volume 17, Issue 12 , Page e013208, December 1, 2024. BACKGROUND:The pentaspline pulsed field ablation catheter achieves pulmonary vein isolation using 8 stacked, pose-specific applications with rotation. versus 6.12.0 mm;P=0.02).

Ablation 40

Ablation Pulmonary Electrophysiology Arrhythmia 40

Journal of Cardiovascular Electrophysiology

NOVEMBER 11, 2024

This study of 16 patients with persistent left superior vena cava (PLSVC) undergoing atrial fibrillation ablation shows a 66.7% identification rate of PLSVC-related triggers and an 85% success rate in acute isolation or targeted ablation. The recurrence rate of arrhythmia postablation was 46.7% However, a 46.7% years, 31.2%

Atrial Fibrillation 40

Atrial Fibrillation Ablation Outcomes Pulmonary 40

Journal of Cardiovascular Electrophysiology

JANUARY 28, 2024

Abstract Introduction During atrial fibrillation ablation (AFA), achievement of first pass isolation (FPI) reflects effective lesion formation and predicts long-term freedom from arrhythmia recurrence. We aim to determine the clinical and procedural predictors of pulmonary vein FPI.

Ablation 40

Ablation Pulmonary BMI Atrial Fibrillation 40

Journal of Cardiovascular Electrophysiology

DECEMBER 7, 2023

Abstract Introduction Cryoballoon ablation (CBA) of the left atrial (LA) roof in addition to a pulmonary vein isolation has been expected to improve the clinical outcomes post-atrial fibrillation (AF) ablation. The 1-year Kaplan–Meier atrial arrhythmia free rate estimates were 80.6% C for Group A vs. −40.5 ± 7.5°C

Ablation 40

Ablation Pulmonary Atrial Fibrillation Arrhythmia 40

Journal of Cardiovascular Electrophysiology

DECEMBER 7, 2023

We present the long-term outcome of catheter ablation (CA) and electrophysiological characteristics in HIV+ AF patients. During first procedure, all received isolation of pulmonary vein (PV) + posterior wall and superior vena cava. Among patients that underwent redo ablation non-PV triggers were higher in HIV group [93.5%

Atrial Fibrillation 40

Atrial Fibrillation Ablation Outcomes Arrhythmia 40

Journal of Cardiovascular Electrophysiology

JANUARY 28, 2024

Abstract Introduction The optimized ablation index (AI) value for catheter ablation of atrial fibrillation (AF) remains to be defined. Methods and Results Patients with symptomatic, drug-resistant paroxysmal AF for first ablation were prospectively enrolled from September 2020 to January 2022. vs. 53.3%, p  = .005).

Atrial Fibrillation 40

Atrial Fibrillation Ablation Arrhythmia Pulmonary 40

HeartRhythm

FEBRUARY 15, 2024

Pulmonary vein isolation (PVI) has been established as a cornerstone therapy for atrial fibrillation (AF). 1 Several studies have highlighted the significant role of non-pulmonary premature atrial complexes (non-PV PACs) in triggering AF/AT episodes.2,3

Atrial Fibrillation 40

Atrial Fibrillation Arrhythmia Pulmonary Ablation 40